Omalizumab

Asthma

Novartismonoclonal_antibodyPhase 3Dormant

BB

68/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 54/ 100
Competitive Position: 95/ 100

Competitive context

12 Active assets in the Asthma cohort.

Asset / Sponsor	Phase	Rating
Budesonide New York City Health and Hospitals Corporation	Phase 4	BBB
SALMETEROL Mundipharma (China) Pharmaceutical Co. Ltd	Phase 4	BBB
Flixotide GlaxoSmithKline	Phase 4	BBB
Montelukast Kafrelsheikh University	Phase 4	BBB
MK-0476 Organon and Co	Phase 4	BB

View all 48 →

Same molecule, other indications

Omalizumab is also rated in:

allergic asthmaDormant

BBB

Indicative ·

76 / 100

chronic rhinosinusitisDormant

BB

Indicative ·

65 / 100

allergic bronchopulmonary aspergillosisDormant

BB

Indicative ·

65 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.